Retatrutide is our AL‑M series multi-receptor agonist, designed for researchers mapping complex metabolic signalling. As a single peptide engaging GLP‑1, GIP, and glucagon receptor pathways, it allows precise interrogation of incretin-related networks, dose - response behaviour, and receptor crosstalk in vitro.

We supply Retatrutide in a research-grade format suitable for endocrine modelling, pharmacodynamic profiling, and comparative studies alongside other incretin-mimetic peptides. Consistent batch specifications and verifiable testing (COA available on request) support reproducible experimental design for data-driven teams.

For projects requiring higher total peptide content, we also carry larger Retatrutide vial strengths within the same classification framework, allowing scaling without changing compound identity.

Disclaimer: Research use only. Not for human or animal use or consumption.